| Variable | At 14 4eeks | At 26 weeks | ||||
| Change placebo (n = 7) | Change infliximab (n = 10) | Mann–Whitney U p Value | Change placebo (n = 7) | Change infliximab (n = 10) | Mann–Whitney U p Value | |
| EMS | 0 (−90 to 0) | −30 (−120 to 3.75) | 0.669 | 0 (−90 to 0) | −28 (−64 to 60) | 0.962 |
| Pain VAS | −13 (−24 to 10) | −19 (−41 to 26) | 0.887 | −24 (−35 to 10) | −12 (−37 to 15) | 0.669 |
| Patient global VAS | −3 (−25 to −1) | −17 (−34 to 7) | 0.962 | −24 (−41 to −2) | −16 (−35 to 10) | 0.475 |
| Physician global VAS | 9 (−22 to 25) | −6 (−44 to 10) | 0.181 | −20 (−31 to 12) | −16 (−40 to 10) | 0.607 |
| Fatigue VAS | −25 (−43 to 1) | 5 (−12 to 14) | 0.193 | −37 (−43 to 1) | −2 (−20 to 14) | 0.043 |
| CRP | 16 (−7 to 67) | −6 (−18 to 3) | 0.088 | −4 (−18 to 48) | −7 (−18 to 10) | 0.536 |
| TJC68 | 0 (−15 to 10) | −13 (−16 to 0) | 0.364 | 0 (−24 to 5) | −11 (−16 to −5) | 0.364 |
| SJC66 | −1 (−7 to 3) | −6 (−9 to −1) | 0.133 | −1 (−6 to 2) | −5 (−9 to 2) | 0.417 |
| HAQ score | −0.500 (−0.625 to 0.000) | −0.875 (−1.063 to −0.375) | 0.088 | −0.50 (−0.63 to −0.13) | −0.94 (−1.03 to −0.13) | 0.193 |
No significant difference between the infliximab and placebo groups was seen for any secondary outcome measure.
CRP, C-reactive protein; EMS, early morning stiffness; HAQ, Health Assessment Questionnaire; SJC66, number of swollen joints, of 66 joints assessed; TJC68, number of tender joints, of 68 joints assessed; VAS, visual analogue score along a 100 mm scale.